EPICHRONIC II

Chronic Diseases – Type 2 Diabetes

Impact of new antidiabetic drugs on the treatment of type 2 diabetes and patients safety: a pharmacoepidemiological challenge

A huge increase of the prevalence of Type 2 diabetes (T2D) has been observed in Europe.
Considering the increasing number of new antidiabetic drugs recently available on the market, there is a need to better define their place in the management of T2D in the real life context.
These new patterns of use should be clearly identified, focusing on patients’ adherence and to expected and unexpected outcomes, in order to early identify potential adverse events of these new drugs.

The EPICHRONIC study was dedicated at assessing the possibility of joint procedures in French and Spanish electronic health databases to carry out large-scale epidemiologic studies in chronic diseases.
This study demonstrated the feasibility to assess the prevalence of T2D through health care databases available of both sides of the Pyrenees mountains.
The objective of this new project is now to implement more focused and longitudinal investigations in the area of T2D, by building a large population-based cohort of incident T2D patients, to investigate real patterns of treatment and its related issues.

Project partners

Project manager : Maryse LAPEYRE-MESTRE
Université Paul Sabatier Toulouse

Researchers or companies, wish to join the REFBIO network?